1. Home
  2. CNTB vs TNYA Comparison

CNTB vs TNYA Comparison

Compare CNTB & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Connect Biopharma Holdings Limited

CNTB

Connect Biopharma Holdings Limited

N/A

Current Price

$0.62

Market Cap

140.4M

Sector

Health Care

ML Signal

N/A

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

N/A

Current Price

$0.30

Market Cap

153.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNTB
TNYA
Founded
2012
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
140.4M
153.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
CNTB
TNYA
Price
$0.62
$0.30
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
★ $5.71
$3.67
AVG Volume (30 Days)
599.6K
★ 2.3M
Earning Date
11-16-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 54.96
EPS
N/A
★ N/A
Revenue
★ $64,000.00
N/A
Revenue This Year
$7,473.67
N/A
Revenue Next Year
$240.46
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.55
$0.30
52 Week High
$3.82
$1.46

Technical Indicators

Market Signals
Indicator
CNTB
TNYA
Relative Strength Index (RSI) 36.76 27.93
Support Level N/A N/A
Resistance Level $2.62 $0.42
Average True Range (ATR) 0.07 0.03
MACD 0.01 0.00
Stochastic Oscillator 33.75 6.46

Price Performance

Historical Comparison
CNTB
TNYA

About CNTB Connect Biopharma Holdings Limited

Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

Share on Social Networks: